September 18, 2026 8:05am EDT XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
September 10, 2026 4:05pm EDT XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™